Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
S1P Asset Will Add To JAK-Heavy Pipeline
Executive Summary
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
You may also be interested in...
Pfizer Gets First Approval Of Arena’s Etrasimod, In Ulcerative Colitis
Branded as Velsipity, the S1P modulator will compete directly against classmate Zeposia in UC and faces a crowded field of anti-TNFs and other types of therapy. Pfizer paid $6.7bn for Arena in 2021.
ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines
ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.